7th TPD and Induced Proximity Summit

With a flurry of high capital collaborations and partnership deals from the likes of C4T, Merck US and KgGA, Monte Rosa, Proxygen, Orum, and momentum building in clinic with BTK degraders, ER degraders and many more assets, it has never been more import to re-join forces at the 7th TPD and Induced Proximity Summit, the longest standing and most comprehensive protein degradation and proximity based conference, returning to Downtown Boston, October 28 - 31, 2024.

Spanning foundational research and discovery, through to IND-filing and clinical trials, this is the world's definitive meeting to discuss opportunities and challenges the TPD and Induced Proximity field must address to expand the target space and facilitate the discovery and development of therapeutically relevant degraders, blockers, stabilizers and inducers of protein-protein interactions. Whether you're entering the TPD and Induced Proximity space for the first time or a well-seasoned TPD veteran, this forum will equip you with the knowhow and connections to make rapid advances in your work.

Assembling over 550 TPD and Induced Proximity enthusiasts from across every corner of the landscape, we have left no stone unturned in our duty to continue to deliver the full breadth and depth of protein degradation and modulation research with SureTACs, EpiTACs, RIPTACs, Molecular Gates, and so much more.

The 7th TPD and Induced Proximity Summit is the field's singular, one-stop-shop to gain unparalleled overview of cutting-edge R and D, whilst diving deep into end-to-end development strategy to propel degraders towards the first clinical approval.

URLs:
Website: https://go.evvnt.com/2481570-0?pid=10018
Tickets: https://go.evvnt.com/2481570-2?pid=10018
Brochure: https://go.evvnt.com/2481570-3?pid=10018

Prices:
Drug Developer Pricing - (4 Day Pass) Industry Days + New Frontiers Day + Next Generation Day: USD 6295.00,
Drug Developer Pricing - (3 Day Pass) Industry Days + New Frontiers Day OR Next Generation Day: USD 4797.00,
Drug Developer Pricing - (2 Day Pass) Industry Days Only: USD 3299.00,
Academic Pricing - (4 Day Pass) Industry Days + New Frontiers Day + Next Generation Day: USD 5495.00,
Academic Pricing - (3 Day Pass) Industry Days + New Frontiers Day OR Next Generation Day: USD 4197.00,
Academic Pricing - (2 Day Pass) Industry Days Only: USD 2899.00,
Service Provider Pricing - (4 Day Pass) Industry Days + New Frontiers Day + Next Generation Day: USD 7295.00,
Service Provider Pricing - (3 Day Pass) Industry Days + New Frontiers Day OR Next Generation Day: USD 5597.00,
Service Provider Pricing - (2 Day Pass) Industry Days Only: USD 3899.00

Speakers: Abhishek Dogra, Director, Medicinal Chemistry and Induced Proximity, A-Alpha Bio, Adrian Gottschalk, President and Chief Executive Officer, Foghorn Therapeutics, Alessio Ciulli, Director of the Centre for Targeted Protein Degradation, University of Dundee, Amine Sadok, Director, Induced Proximity Platform, Amgen, Andreas Reichel, Vice President, Head Of DMPK Modelling and Simulations, Bayer, Andrew Tsourkas, Professor, University of Pennsylvania, Anita C. Bellail, Chief Scientific Officer and Co-Founder, HB Therapeutics, Ankit Sharma, Associate Director, Medicinal Chemistry, Oncology Targeted Discovery, AstraZeneca, Arnout Schepers, Founder and Chief Executive Officer, TenAces Biosciences, Arthur Sands, President and Chief Executive Officer, Nurix Therapeutics, Arvind Shakya, Director, BioTheryx, Barbara Lueckel, Global Head, Research Technologies Partnering, Pharma Partnering, F. Hoffmann-La Roche, Benedict Cross, CTO, Phoremost, Bernd Boidol, Chief Executive Officer, Proxygen, Bradlee Heckmann, Chief Scientific Officer, Asha Therapeutics, Carolyn Porter, Chief Executive Officer, Outrun Therapeutics, Charu Chaudhry, Senior Principal Scientist, Novartis, Chinatsu Sakata-Sakur, Vice President, Astellas Pharma, Christian Dillon, Chief Scientific Officer, PhoreMost, Christian Ottmann, Associate Professor, Eindhoven University of Technology, Christina Woo, Associate Professor, Harvard University, Dan Finley, Professor, Harvard Medical School, Diogo Feleciano, Co-Founder and Chief Operating Officer, Booster Therapeutics, Dmitri Ivanov, Associate Professor, UT Health San Antonio, Effie Tozzo, Chief Scientific Officer, Avilar Therapeutics, Elena De Vita, Assistant Professor, Queen Mary University of London, Elizabeth Caine, Scientist, Promega, Eric Fischer, Professor and Director Chemical Biology Program Harvard Medical School - Director - DFCI, Center for Protein Degradation, Eugene Chekler, Director, Bristol Myers Squibb, Gang Yao, Associate Director Encoded Oncology, GSK, Gary Kleiger, Chair and Professor, University of Las Vegas, Nevada, Giovanni Spagnolli, Co-Founder and Chief Technology Officer, Sibylla Biotech, Gisele Nishiguchi, Group Leader, St. Jude Children's Research Hospital, Greg Michaud, Director, Novartis AG, Hailong Zhang, Chief Executive Officer, Blueray Biopharma, Henrik Daub, Founder and Chief Scientific Officer, NEOsphere Biotechnologies, Ian Churcher, Consultant, Janus Drug Discovery, Jaehyun Choi, Chief Executive Officer, EPD Biotherapeutics, James Papatzimas, Principal Scientist, Novartis, Jason Kantor, Chief Business Officer, Nurix Therapeutics, Jessica Sims, Principal Scientist Toxicology, Genentech, JF Brazeau, Director, Plexium, Jian Jin, Mount Sinai Endowed Professor, Icahn School of Medicine at Mount Sinai, Joachim Rudolph, Senior Fellow Discovery Chemistry, Genentech, Johan Johansson, Associate Principal Scientist, CVRM PROTAC Lead, Project Leader, AstraZeneca, John Houston, Chairperson, Chief Executive Officer, and President, Arvinas, Juliet Williams, Head of Research, Kymera Therapeutics, Kanak Raina, Senior Director Biology, Halda Therapeutics, Karteek Kadimisetty, Director, LifeSensors, Ken Yamada, Associate Director, Novartis, Keunsoo Kang, Chief Scientific Officer, Deargen, Kylie Walters, Senior Investigator and Section Chief, National Institutes of Health, Len Reyno, Chief Medical Officer, C4 Therapeutics, Leo Fu, Co-Founder and Chief Technology Officer, GluBio Therapeutics, Lise Loberg, Preclinical Safety Expert, AbbVie, Magnus Walter, Senior Vice President Drug Discovery, Monte Rosa Therapeutics, Mark Niosi, Principal Scientist, Pfizer, Matthias Brand, Co-Founder and Chief Scientific Officer, Proxygen, Maureen Spit, Vice President Research, Laigo Bio, Nadeem Vellore, Principal Scientist, Johnson and Johnson, Nan Ji, Co-Founder, President and Chief Executive Officer, PAQ Therapeutics, Natalie Nairn, Co-Founder, Chief Executive Officer and Chief Scientific Officer, Cyclera Therapeutics, Neil Bence, Site Head and Vice President, Bristol Myers Squibb, Nello Mainolfi, Chief Executive Officer, Kymera Therapeutics, Pat Sharp, Senior Vice President Discovery Sciences, Gate Bioscience, Paula O'Connor, Chief Medical Officer, Nurix Therapeutics, Peggy Scherle, Chief Scientific Officer, Prelude Therapeutics, Radoslav Enchev, Group Leader, The Francis Crick Institute, Raegan O'Lone, Senior Program Advisor, HESI, Randolph Lopez, Co-Founder and Chief Technology Officer, A-Alpha Bio, Randy Teel, Chief Business Officer, Arvinas, Riccardo Sabatini, Chief Data Scientist, Orionis Biosciences, Rick Ewing, Vice President Head of Chemistry, Rapafusyn, Ryan Kerrigan, Principal Scientist, Novartis, Scott Boyle, Chief Business Officer, C4 Therapeutics, Sharon Townson, Chief Technology Officer, Monte Rosa Therapeutics, Shyra Gardai, Chief Scientific Officer, EpiBiologics, Stephanie Leuenroth-Quinn, Pharmacologist, FDA, Steven Banik, Assistant Professor, Stanford University, Steven Bellon, Chief Scientific Officer, Foghorn Therapeutics, Stewart Fisher, Chief Scientific Officer, C4 Therapeutics, Stuart Schreiber, Founding Chief Executive Officer, Arena Bioworks, William Housley, Principal Research Scientist, Abbvie, Wu Du, Senior Vice President Medicinal Chemistry, Hinova Pharmaceuticals, Xiaoran Han, Vice President, Discovery Medicine, Cullgen, Ya-Wen, Lu Associate Director, Nurix Therapeutics, Yao Wang, Chief Medical Officer, Kangpu Biopharmaceuticals, Yong Cang, Co-Founder and Chief Scientific Officer, Degron Therapeutics, Zoran Rankovic, Director, Centre for Protein Degradation, The Institute for Cancer Research